Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.

Kikuchi T, Mimura K, Okayama H, Nakayama Y, Saito K, Yamada L, Endo E, Sakamoto W, Fujita S, Endo H, Saito M, Momma T, Saze Z, Ohki S, Kono K.

Oncol Lett. 2019 Dec;18(6):5977-5985. doi: 10.3892/ol.2019.10953. Epub 2019 Oct 2.

2.

The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.

Toh JWT, de Souza P, Lim SH, Singh P, Chua W, Ng W, Spring KJ.

Clin Colorectal Cancer. 2016 Dec;15(4):285-291. doi: 10.1016/j.clcc.2016.07.007. Epub 2016 Jul 22. Review.

PMID:
27553906
3.

The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance.

Feng YC, Ji WL, Yue N, Huang YC, Ma XM.

Cancer Manag Res. 2018 Jan 18;10:105-113. doi: 10.2147/CMAR.S152232. eCollection 2018.

4.
5.

Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.

Le Flahec G, Badic B, Guibourg B, Doucet L, Bail JP, Marcorelles P, Schick U, Uguen A.

Hum Pathol. 2018 Feb;72:135-143. doi: 10.1016/j.humpath.2017.09.019. Epub 2017 Dec 5.

PMID:
29208565
6.

Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer.

Liu S, Kong P, Wang X, Yang L, Jiang C, He W, Quan Q, Huang J, Xie Q, Xia X, Zhang B, Xia L.

Oncol Lett. 2019 Feb;17(2):2335-2343. doi: 10.3892/ol.2018.9826. Epub 2018 Dec 12.

7.

Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.

Korehisa S, Oki E, Iimori M, Nakaji Y, Shimokawa M, Saeki H, Okano S, Oda Y, Maehara Y.

Int J Cancer. 2018 Feb 15;142(4):822-832. doi: 10.1002/ijc.31107. Epub 2017 Oct 31.

8.

Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.

Li Y, Liang L, Dai W, Cai G, Xu Y, Li X, Li Q, Cai S.

Mol Cancer. 2016 Aug 24;15(1):55. doi: 10.1186/s12943-016-0539-x.

9.

Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.

Kong P, Wang J, Song Z, Liu S, He W, Jiang C, Xie Q, Yang L, Xia X, Xia L.

J Cancer. 2019 Apr 5;10(7):1745-1754. doi: 10.7150/jca.25187. eCollection 2019.

10.

Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer.

Lee KS, Kwak Y, Ahn S, Shin E, Oh HK, Kim DW, Kang SB, Choe G, Kim WH, Lee HS.

Cancer Immunol Immunother. 2017 Jul;66(7):927-939. doi: 10.1007/s00262-017-1999-6. Epub 2017 Apr 12.

PMID:
28405764
11.

Impact of mismatch-repair deficiency on the colorectal cancer immune microenvironment.

Zhang Y, Sun Z, Mao X, Wu H, Luo F, Wu X, Zhou L, Qin J, Zhao L, Bai C.

Oncotarget. 2017 Aug 14;8(49):85526-85536. doi: 10.18632/oncotarget.20241. eCollection 2017 Oct 17.

12.

Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.

Schiemann U, Müller-Koch Y, Gross M, Daum J, Lohse P, Baretton G, Muders M, Mussack T, Kopp R, Holinski-Feder E.

Digestion. 2004;69(3):166-76. Epub 2004 Apr 28.

PMID:
15118395
13.

Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.

Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A, Rosso R, Zuber M, Muraro MG, Amicarella F, Cremonesi E, Heberer M, Iezzi G, Lugli A, Terracciano L, Sconocchia G, Oertli D, Spagnoli GC, Tornillo L.

Eur J Cancer. 2013 Jun;49(9):2233-42. doi: 10.1016/j.ejca.2013.02.015. Epub 2013 Mar 13.

PMID:
23478000
14.

Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.

Ma C, Patel K, Singhi AD, Ren B, Zhu B, Shaikh F, Sun W.

Am J Surg Pathol. 2016 Nov;40(11):1496-1506.

PMID:
27465786
15.

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.

Taieb J, Shi Q, Pederson L, Alberts S, Wolmark N, Van Cutsem E, de Gramont A, Kerr R, Grothey A, Lonardi S, Yoshino T, Yothers G, Sinicrope FA, Zaanan A, André T.

Ann Oncol. 2019 Sep 1;30(9):1466-1471. doi: 10.1093/annonc/mdz208.

PMID:
31268130
16.

Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer.

Li YM, Yu JM, Liu ZY, Yang HJ, Tang J, Chen ZN.

Int J Mol Sci. 2019 Oct 17;20(20). pii: E5138. doi: 10.3390/ijms20205138.

17.

Increased CD8 Tumor Infiltrating Lymphocytes in Colorectal Cancer Microenvironment Supports an Adaptive Immune Resistance Mechanism of PD-L1 Expression.

Sudoyo AW, Kurniawan AN, Kusumo GD, Putra TP, Rexana FA, Yunus M, Budiyati AD, Kurniawan D, Utama A, Utomo AR.

Asian Pac J Cancer Prev. 2019 Nov 1;20(11):3421-3427. doi: 10.31557/APJCP.2019.20.11.3421.

18.
19.

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.

Abida W, Cheng ML, Armenia J, Middha S, Autio KA, Vargas HA, Rathkopf D, Morris MJ, Danila DC, Slovin SF, Carbone E, Barnett ES, Hullings M, Hechtman JF, Zehir A, Shia J, Jonsson P, Stadler ZK, Srinivasan P, Laudone VP, Reuter V, Wolchok JD, Socci ND, Taylor BS, Berger MF, Kantoff PW, Sawyers CL, Schultz N, Solit DB, Gopalan A, Scher HI.

JAMA Oncol. 2019 Apr 1;5(4):471-478. doi: 10.1001/jamaoncol.2018.5801.

20.

EBV⁺ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8⁺ Intratumoral Lymphocytes.

De Rosa S, Sahnane N, Tibiletti MG, Magnoli F, Vanoli A, Sessa F, Chiaravalli AM.

Cancers (Basel). 2018 Apr 1;10(4). pii: E102. doi: 10.3390/cancers10040102.

Supplemental Content

Support Center